Radiation and immunotherapy join forces against tough pancreatic cancer

NCT ID NCT07312422

Recruiting now Disease control Sponsor: Zhejiang Provincial People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing whether adding low-dose radiation and an immunotherapy drug called pucotenlimab to standard chemotherapy can help control advanced pancreatic cancer. Ten adults with pancreatic cancer who haven't had prior immunotherapy will receive the combination. The goal is to see if the treatment shrinks tumors and improves disease control, while also identifying which patients benefit most.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: low-dose radiation, pucotenlimab (a PD-1 inhibitor), gemcitabine, nab-paclitaxel, oxaliplatin, irinotecan, leucovorin, and 5-FU
What this could lead to: If it works, this could point toward a new combination therapy that helps control advanced pancreatic cancer by activating the immune system.
What could go wrong: This is a very early, small trial with only 10 participants, so results may not apply widely. The combination also carries risks like immune-related side effects and chemotherapy toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LDRT PANCREATIC CANCER PD-1 INHIBITOR PD-L1 PROTERIZUMAB

Contacts and locations

Locations

Zhejiang Provincial People's Hospital
RECRUITING

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.